Michael Anstey

Mike graduated with a 1st Class Honors degree in Biology from Queen's University, Canada, and earned his DPhil in Zoology from Oxford University, where he was the Hope Scholar.

Dr Michael Anstey is a Partner specializing in life science investments. 

​

Before joining CIC he was a Principal in the Healthcare Practice Area at The Boston Consulting Group's (BCG) Toronto office. Michael has experience in advising multinational businesses across North America, Europe, India, and Japan. 

​

Michael was also co-founder of an early stage biotechnology company focused on developing small molecule drugs that target protein-protein interactions implicated in disease. Prior to BCG, Michael worked at Oxford Capital Partners, where he focused on investing in early stage life science businesses. 

​

Michael manages CIC's investments in Bicycle Therapeutics (NASDAQ: BCYC), Congenica, Immutrin, PredictImmune, PolyProx Therapeutics, Sense Bio, Start Codon and Storm Therapeutics.

Michael served his fellowship at Cambridge Innovation Capital under the mentorship of Victor Christou. He is a member of Class 22.